Hunan Er Kang Pharmaceutical (300267) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Hunan Er Kang Pharmaceutical ¥0.39, price ¥3.38, upside -88.5%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hunan Er Kang Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥2.06 – ¥5.11 · fair‑value band ¥0.3800 – ¥0.4000 · the ¥3.38 price screens above the ¥0.3900 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Hunan Er Kang Pharmaceutical in your weekly email
Every Wednesday you see whether Hunan Er Kang Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally.
Show more
Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.
Stock analysis
Hunan Er Kang Pharmaceutical (300267) currently trades at ¥3.38, while our model-based Fair Value estimate is ¥0.3900, implying the stock looks roughly 766.6% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥1.31 per share, and 0 of the 13 models we run sit above the ¥3.38 price.
Bear case: the Earnings-Based group reads lowest at ¥0.3900, and 13 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.3800 (bear) to ¥0.4000 (bull), the price of ¥3.38 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Hunan Er Kang Pharmaceutical reported revenue of 1.2B CNY in FY2025 versus 2.2B CNY in FY2021, a compound −15.0%/yr. Reported net income was −380M CNY in FY2025.
Key figures
Market cap 7.0B CNY (≈ $1.0B) · P/S ratio 6.89 · EPS (TTM) ¥−0.1900 · Dividend yield 0.2% · Net margin −32.6% · Return on equity −9.9% · Return on assets (EBIT) −5.1% · Operating margin 2.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 30% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −88%, 300267 screens richer than that median.
Fair Value models
Bear ¥0.3800Fair Value ¥0.3900Bull ¥0.4000
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.3%
Start year 2020 (pandemic). Over 10 years: −4.0% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.1% (2020) → 1.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +34.7% a year for the price.
Compare Hunan Er Kang Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−89% · Bottom 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−37% · Bottom 25%
Operating margin (TTM)2% · Below median
Growth and dividend
Revenue growth−30% · Bottom 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.26× · Cheapest 25%
P/S (TTM)0.98× · Cheaper than median
P/FCF11.1× · Priciest 25%
EV/EBITDA3.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 27
HEALTH (low debt)98· sector 96
DIVIDEND (yield)3· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hunan Er Kang Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/300267
Frequently asked questions
Is Hunan Er Kang Pharmaceutical (300267) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥0.3900 versus a price of ¥3.38, about −88% upside (overvalued).
What is the fair value of 300267?
Our model-based fair value for Hunan Er Kang Pharmaceutical is ¥0.3900 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥3.38.
What is the quality score of 300267?
Hunan Er Kang Pharmaceutical has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hunan Er Kang Pharmaceutical (300267)?
Our model-based price target is the fair value of ¥0.3900 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario ¥0.3800, optimistic scenario ¥0.4000. It is a calculation from audited fundamentals, not an analyst target.
What is the Hunan Er Kang Pharmaceutical stock forecast for 2026?
Our models put fair value at ¥0.3900, about −88% upside versus a price of ¥3.38 (overvalued). Cautious scenario ¥0.3800, optimistic scenario ¥0.4000. The calculation is refreshed regularly with new filings.
What is the revenue of Hunan Er Kang Pharmaceutical (300267)?
Hunan Er Kang Pharmaceutical reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Sep 24, 2026).
Does Hunan Er Kang Pharmaceutical pay a dividend?
Hunan Er Kang Pharmaceutical currently shows a dividend yield of about 0.15% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Hunan Er Kang Pharmaceutical (300267)?
For today's price to be fair in a discounted-cash-flow model, Hunan Er Kang Pharmaceutical would have to grow free cash flow by +37.0 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 300267 use?
Our models discount Hunan Er Kang Pharmaceutical at 10.4 %: a base by market capitalisation (small), damped by beta 0.41, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hunan Er Kang Pharmaceutical that is +37.0 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Hunan Er Kang Pharmaceutical (300267) delivered so far?
Over the past 5 years revenue at Hunan Er Kang Pharmaceutical grew -13.3 % a year. The price currently implies +37.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hunan Er Kang Pharmaceutical (300267) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Hunan Er Kang Pharmaceutical (+37.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hunan Er Kang Pharmaceutical (300267)?
The free-cash-flow yield on the price is 1.34 %: that much free cash flow Hunan Er Kang Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hunan Er Kang Pharmaceutical (300267)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hunan Er Kang Pharmaceutical it is ¥0.3900 per share (as of Sep 24, 2026), against a price of ¥3.38. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Hunan Er Kang Pharmaceutical stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300267 trades above its calculated fair value: price ¥3.38, fair value ¥0.3900, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300267?
No. The price is what the market pays today (¥3.38); the fair value is what the company's own numbers justify (¥0.3900). For Hunan Er Kang Pharmaceutical the two are ¥2.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hunan Er Kang Pharmaceutical worth?
The market values Hunan Er Kang Pharmaceutical at about 7.0B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥3.38; our models calculate a fair value of ¥0.3900 per share.
What do the bullish and bearish scenarios say about 300267?
Our models span a range for Hunan Er Kang Pharmaceutical: cautious scenario ¥0.3800, base ¥0.3900, optimistic ¥0.4000 per share (as of Sep 24, 2026, price ¥3.38). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hunan Er Kang Pharmaceutical (300267)?
Balance-sheet figures for Hunan Er Kang Pharmaceutical (as of Sep 24, 2026): return on equity −9.9%, debt of 0.05 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 300267 from its 52-week high?
Hunan Er Kang Pharmaceutical trades at ¥3.38, about 30% below its 52-week high of ¥4.84 and 17% above the low of ¥2.88 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.3900 is for.
Which stocks are comparable to Hunan Er Kang Pharmaceutical?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hunan Er Kang Pharmaceutical stock attractive at the current price?
The data as of Sep 24, 2026: price ¥3.38, calculated fair value ¥0.3900 (−88%), Quality Score 49/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300267 calculated?
We run Hunan Er Kang Pharmaceutical through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.3900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hunan Er Kang Pharmaceutical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hunan Er Kang Pharmaceutical (300267)?
The closing price on Sep 22, 2026 was ¥3.38. Our model-based fair value is ¥0.3900, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hunan Er Kang Pharmaceutical right now?
The price sits above even our optimistic bull case (¥0.4000). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥0.3800 to ¥0.4000), unusually little disagreement for a valuation.
Key figures of Hunan Er Kang Pharmaceutical
How large is the market capitalisation of Hunan Er Kang Pharmaceutical (300267)?
The market capitalisation of Hunan Er Kang Pharmaceutical is 7.0B CNY (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hunan Er Kang Pharmaceutical (300267)?
The price-to-sales ratio of Hunan Er Kang Pharmaceutical is 6.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hunan Er Kang Pharmaceutical (300267)?
Earnings per share at Hunan Er Kang Pharmaceutical are ¥−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hunan Er Kang Pharmaceutical (300267)?
The dividend yield of Hunan Er Kang Pharmaceutical is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hunan Er Kang Pharmaceutical (300267)?
The net margin of Hunan Er Kang Pharmaceutical is −32.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hunan Er Kang Pharmaceutical (300267)?
The return on equity (ROE) of Hunan Er Kang Pharmaceutical is −9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hunan Er Kang Pharmaceutical (300267)?
On an EBIT basis the return on assets of Hunan Er Kang Pharmaceutical is −5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hunan Er Kang Pharmaceutical (300267)?
The operating margin of Hunan Er Kang Pharmaceutical is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hunan Er Kang Pharmaceutical (300267)?
Revenue at Hunan Er Kang Pharmaceutical is growing −30.0% versus a year earlier (3y avg −14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hunan Er Kang Pharmaceutical (300267)?
Earnings per share at Hunan Er Kang Pharmaceutical are growing −52.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Hunan Er Kang Pharmaceutical (300267) hold?
Hunan Er Kang Pharmaceutical holds more cash than debt, 193M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Hunan Er Kang Pharmaceutical in the live analysis
One click puts Hunan Er Kang Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
